In addition, the mechanisms of ATO cytotoxicity also rely in degradation of the leukemia fusion protein, namely PML-retinoic acid receptor alpha (PML-RARα) restoring PML functions [10, 11]. The gene discussed is RARA; the disease is leukemia.